Sugi Predict

Sugi Predict / Compounds / SCHEMBL16793852

SCHEMBL16793852

SCHEMBL16793852

Cc1cc(B2OC(C)(C)C(C)(C)O2)ccc1CNC(=O)N1CC(OC(C)C)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 5/20 0.47
▸ AAK1 Q2M2I8 2/20 0.47
▸ JAK2 O60674 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ HRH2 P25021 1/20 0.47
▸ CDK7 P50613 1/20 0.47
▸ CD69 Q07108 1/20 0.47
▸ MAP3K19 Q56UN5 1/20 0.47
▸ CDKL2 Q92772 1/20 0.47
▸ RIOK1 Q9BRS2 1/20 0.47
▸ RIOK2 Q9BVS4 1/20 0.47
▸ BMP2K Q9NSY1 1/20 0.47
▸ ROCK1 Q13464 1/20 0.39
▸ BACE1 P56817 3/20 0.35
▸ EPHX2 P34913 3/20 0.34
▸ HIF1A Q16665 2/20 0.34
▸ PRMT5 O14744 1/20 0.33
▸ WDR77 Q9BQA1 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20027005 0.92 BTK (0.41) BTKAAK1JAK2CYP3A4HRH2
SCHEMBL20027003 0.89 BTK (0.45) BTKAAK1JAK2CYP3A4HRH2
SCHEMBL25176701 0.84 ROCK1 (0.40) BTKAAK1JAK2CYP3A4HRH2
SCHEMBL18183911 0.82 BTK (0.48) BTKAAK1JAK2CYP3A4HRH2
SCHEMBL25590604 0.79 BTK (0.53) BTKAAK1JAK2CYP3A4HRH2
SCHEMBL16793564 0.79 BTK (0.53) BTKAAK1JAK2CYP3A4HRH2
SCHEMBL16794462 0.76 NPC1 (0.43) AAK1ROCK1EPHX2HIF1APRMT5
SCHEMBL18183922 0.75 BTK (0.54) BTKROCK1EPHX2PRMT5WDR77
SCHEMBL29547987 0.74 NPC1 (0.41) AAK1ROCK1HIF1APRMT5WDR77
SCHEMBL24270172 0.74 NPC1 (0.41) AAK1ROCK1HIF1APRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250041429-A1 COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF UBIX THERAPEUTICS, INC. (KR) 2025-02-06 — — US disclosed
EP-4428130-A1 COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF Ubix Therapeutics, Inc. (KR) 2024-09-11 — — EP disclosed
CN-118159532-A Compound with BTK protein degradation activity and medical application thereof 尤比克斯治疗公司 2024-06-07 — — CN disclosed
WO-2023183652-A1 DUAL CXCR4-BTK INHIBITORS X4 PHARMACEUTICALS, INC. (US) 2023-09-28 — — WO disclosed
WO-2023183652-A1 DUAL CXCR4-BTK INHIBITORS X4 PHARMACEUTICALS, INC. (US) 2023-09-28 — — WO disclosed
EP-3444251-B1 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY BIOGEN MA INC (US) 2023-06-07 — — EP disclosed
EP-3444251-B1 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY BIOGEN MA INC (US) 2023-06-07 — — EP disclosed
WO-2023080732-A1 COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF 주식회사 유빅스테라퓨틱스 2023-05-11 — — WO disclosed
US-11572356-B2 Biaryl inhibitors of Bruton's tyrosine kinase BIOGEN MA INC. (US) 2023-02-07 — — US disclosed
US-10759783-B2 Biaryl inhibitors of Bruton'S tyrosine kinase BIOGEN MA INC. (US) 2020-09-01 — — US disclosed
US-20180093973-A1 BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE BIOGEN MA INC. 2018-04-05 — — US disclosed
US-9809577-B2 Biaryl inhibitors of Bruton's tyrosine kinase BIOGEN MA INC. (US) 2017-11-07 — — US disclosed
US-20160318935-A1 BIARYL BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN MA INC. 2016-11-03 — — US disclosed
US-20160318935-A1 BIARYL BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN MA INC. 2016-11-03 — — US disclosed
US-20160318935-A1 BIARYL BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN MA INC. 2016-11-03 — — US disclosed
US-20160311802-A1 BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE BIOGEN MA INC. 2016-10-27 — — US disclosed
EP-3080122-A1 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY Biogen MA Inc. (US) 2016-10-19 — — EP disclosed
WO-2015089327-A1 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY BIOGEN IDEC MA INC. (US) 2015-06-18 — — WO disclosed
WO-2015089337-A1 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY BIOGEN IDEC MA INC. (US) 2015-06-18 — — WO disclosed
WO-2015089327-A1 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY BIOGEN IDEC MA INC. (US) 2015-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572356-B2 Biaryl inhibitors of Bruton's tyrosine kinase ABL1, BTK, LYN BTK 2/4885AAK1 455/4885JAK2 20/4885
US-10759783-B2 Biaryl inhibitors of Bruton'S tyrosine kinase ABL1, BTK, LYN BTK 2/4885AAK1 455/4885JAK2 20/4885
US-20180093973-A1 BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, LYN BTK 2/4885AAK1 455/4885JAK2 20/4885
US-20160318935-A1 BIARYL BRUTON'S TYROSINE KINASE INHIBITORS ABL1, BTK, LYN BTK 2/4885AAK1 532/4885JAK2 20/4885
US-20160311802-A1 BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, LYN BTK 2/4885AAK1 455/4885JAK2 20/4885
US-20250041429-A1 COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF BTK, LYN, SYK BTK 1/4885AAK1 1045/4885JAK2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback